The FDA Plausible Mechanism Framework Just Changed Rare Disease Drug Development

By Leila Cupersmith, CEO, Choice ClinOps

If you lead clinical development at a pharmaceutical, biotech, or biopharma company working in rare or ultra-rare disease, you know the operational reality. Patient populations are extraordinarily small. Diagnoses arrive late — sometimes years after disease onset. Designing a randomized controlled trial for a disease affecting fewer than a dozen patients worldwide has always been, for many programs, both scientifically impractical and ethically out of reach. Randomizing fewer than a dozen known patients worldwide to placebo or non–disease-modifying care is ethically out of reach because it can deny a potentially life-altering therapy to a meaningful fraction of the entire patient population — often children with progressive, irreversible disease — without a proportionate social or scientific benefit. For many of these ultra-rare diseases, every day that passes can translate to permanent loss of function, decreased quality and duration of life.

On February 23, 2026, the FDA released the Plausible Mechanism Framework to establish, for the first time, a formal approval pathway for individualized therapies targeting ultra-rare genetic diseases, including genome editing technologies, such as CRISPR, and RNA-based therapies such as antisense oligonucleotides (ASOs).

This is a structural shift in how approval evidence can be generated and evaluated for programs where conventional clinical trial design does not apply. Every rare and ultra-rare disease sponsor needs to understand it and prepare to take immediate action. Traditional randomized controlled trial frameworks were never designed for this environment. The FDA Plausible Mechanism Framework formally acknowledges that.

Are RCTs Required For Ultra-Rare Disease Approval Under The Plausible Mechanism Framework?

This is the most important question for your leadership and clinical development teams to answer correctly — because it is also the question most likely to be misunderstood.

The short answer: No. RCTs are not required for the individualized therapy programs covered by this framework. The FDA states explicitly in the draft guidance that these are therapies for diseases in a small number of patients "where a randomized controlled trial typically is not feasible." That is a foundational premise of the entire document.

But here is what executives must understand clearly: The FDA has not lowered the evidentiary standard for rare disease drug approval. It has restructured how that evidence is built. The randomized control arm is replaced — not eliminated — by a well-characterized external control drawn from natural history data in untreated patients. The rigor required is equivalent. The architecture is different.

Under the Plausible Mechanism Framework, approval for individualized therapies requires:

• a single adequate and well-controlled clinical investigation — most likely an externally controlled trial comparing the treated patient's trajectory against robust natural history data from untreated patients
• confirmatory evidence from nonclinical or clinical sources: mechanistic data, confirmed target engagement, and exposure-response relationships on biomarkers and clinical outcomes
• prespecified analysis plans with a defined external control established before treatment begins
• a well-characterized natural history of the disease in the untreated population — this is the external control arm, not background context.

For genome editing biological products, sponsors file an IND application to initiate clinical investigation and a BLA for approval. For ASO drug products, the pathway is an IND followed by an NDA. Both are addressed in the draft guidance.

When treatment effects are dramatic, occur rapidly, and are unlikely to have occurred spontaneously, the FDA acknowledges that comparison to the patient's own pretreatment baseline — supported by natural history data and a prospective lead-in period — may be acceptable. This is the closest the framework comes to a single-arm design, and it applies only when those specific conditions are clearly met.

Sponsors who read this framework as permission to submit thin evidence packages will encounter significant regulatory difficulty. Sponsors who read it as a road map for building a different — but equally rigorous — evidence package will be positioned to use it effectively.

What Does The FDA Plausible Mechanism Framework Mean For Rare Disease Clinical Trial Operations?

For CEOs, CMOs, CSOs, and heads of clinical development at rare and ultra-rare disease sponsors, this guidance demands immediate operational action across six areas.

1. Evidence Planning Starts at Patient Identification, Not IND Filing

The first-in-human study will typically be the pivotal study. There is no Phase 1 to prototype your data collection strategy. Your observational protocol must be active from the moment a candidate patient is identified. Manufacturing, nonclinical work, and clinical evidence generation must run in parallel.

ClinOps Optimization Check: If a candidate patient were identified today, do you have an observational protocol ready to activate — and is your team structured to run parallel development tracks from day one?

2. Natural History Data Is Your External Control Arm

Without well-characterized natural history data in the untreated population, you do not have an external control. Without an external control, you do not have an adequate and well-controlled clinical investigation. Address natural history data gaps now through patient registry development, disease foundation partnerships, or academic collaborations.

ClinOps Optimization Check: Can you clearly articulate what your natural history data set looks like, who owns it, and whether it is robust enough for the FDA to distinguish a treatment effect from natural disease variability?

3. Ultra-Rare Disease Patient Identification Requires Relationship Infrastructure

Ultra-rare disease patients are geographically dispersed, frequently undiagnosed when a trial opens, and cared for by a small number of specialists globally. Sponsors need active engagement with patient advocacy organizations, rare disease centers of excellence, decentralized clinical trial capabilities, and caregiver support systems.

ClinOps Optimization Check: Do you have trust-based relationships with the advocacy organizations and specialist centers where your target patients are most likely to be identified — and a caregiver support infrastructure that makes participation realistic?

4. Biomarker Strategy Must Be Validated and Longitudinal

The Plausible Mechanism Framework places significant weight on biomarkers as confirmatory evidence and, for accelerated approval, as surrogate endpoints. Analytically validated biomarker assays must be in place before the IND, with specimen collection built into the protocol with the same rigor as primary endpoints.

ClinOps Optimization Check: Have you prespecified your rare disease biomarker strategy with validated assays and a longitudinal collection plan — or are biomarkers still being treated as secondary to primary clinical endpoints?

5. CMC Development Must Run Concurrently with Clinical Development

The number of manufacturing batches available to validate your process may equal the number of doses needed for the trial. The CMC agenda cannot follow clinical readouts — it must run alongside them. Commercial manufacturing requirements, process validation, and shelf-life data generation must be built into your earliest IND manufacturing runs.

ClinOps Optimization Check: Is your CMC team operating on the same timeline as your clinical and nonclinical teams — or are manufacturing scale and validation questions still being deferred?

6. FDA Regulatory Engagement Must Be Early and Program-Specific

The Plausible Mechanism Framework is guidance, not regulation. Its application to your specific program requires direct, early dialogue with the relevant FDA review division. Pre-IND meeting requests should be a near-term priority for any sponsor whose programs qualify.

ClinOps Optimization Check: Has your regulatory affairs team reviewed this draft guidance against your active programs — and do you have a pre-IND meeting scheduled or a concrete plan to schedule one?

How Do You Submit Comments On The FDA Plausible Mechanism Framework Draft Guidance?

The comment period will close on April 26, 2026 — 60 days from the Federal Register publication date of February 25, 2026 (document number 2026-03713). Submit electronically at Regulations.gov or in writing to the Dockets Management Staff (HFA-305), FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

“Alone we can do so little; together we can do so much,” as Helen Keller has said. For rare and ultra-rare disease sponsors with active development programs, this comment window is a direct opportunity to shape the final guidance. Perspectives on natural history data standards, decentralized rare disease trial design, and CMC validation for limited-batch individualized therapy programs belong in the public record.

Success Scaffolding: 9 Actions Rare And Ultra-Rare Disease Sponsors Must Complete Now

The FDA's regulatory science has moved. Clinical trial operations must move with it. These steps are immediate priorities for executives and ClinOps leaders at rare and ultra-rare disease sponsors to position new programs correctly under this framework and to audit programs already underway.

1. Review the Plausible Mechanism draft guidance in full. Assign your CMO, head of clinical development, and regulatory affairs lead to map every active and pipeline program against the framework's five core criteria: identified abnormality, targeted mechanism, natural history data, confirmed target engagement, and demonstrated clinical improvement before any other planning conversation.
2. Audit your natural history data immediately. Determine whether your existing data is sufficient to serve as an external control. If not, initiate patient registry development, literature synthesis, or partnerships with disease foundations and academic centers with longitudinal data sets.
3. Activate your observational protocol at patient identification. If a candidate patient exists and you do not have a running observational protocol capturing baseline data, start now. Every data point from day one is part of the approval package.
4. Restructure your development timeline for parallel execution. Manufacturing, nonclinical studies, and clinical evidence generation must run simultaneously. Identify where parallel tracks are not currently operational and assign accountability for closing those gaps.
5. Validate and lock your biomarker strategy before IND filing. Prespecify biomarker endpoints, confirm analytical validation of assays, and build longitudinal specimen collection into your protocol with the same rigor as your primary clinical endpoints.
6. Align your CMC team to the clinical timeline. Confirm that commercial manufacturing requirements, process validation, and shelf-life data generation are built into your earliest IND manufacturing runs. For genome editing programs with multiple variants, confirm your potency assay is mutation-adaptable from the start.
7. Build your patient identification infrastructure now. Map the patient advocacy organizations, rare disease centers, and specialist networks relevant to your target population. Establish active relationships and ensure your trial design includes decentralized capabilities and a caregiver support system.
8. Schedule your FDA pre-IND meeting. Request a meeting with the relevant review division specifically to align on how the Plausible Mechanism Framework applies to your program, your molecule, and your current data package.
9. Submit public comments by April 26, 2026. Assign your regulatory affairs leadership to develop and submit formal comments at Regulations.gov (document number 2026-03713). Real-world operational perspectives on natural history data, decentralized trial design, and limited-batch CMC validation will directly influence the final guidance.

The rare and ultra-rare disease sponsors that will define the next decade of individualized therapy development are the ones executing these steps now — not after the first patient is identified and not after the IND or BLA is filed.

About The Author:

Leila Cupersmith has worked hands-on in global clinical trial operations for 21 years and is an advocate for rare disease and oncology patients. She is also the CEO of Choice ClinOps, where she and her team provide fractional, embedded executive clinical trial operations leadership and execution for global rare disease and oncology clinical trial sponsors. She works alongside leadership teams at global pharmaceutical, biotech, and biopharma companies to build and execute the operational infrastructure that rare disease and complex oncology clinical trial programs require — from IND to approval.